I. Svane

发表

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

D. Schadendorf, H. Olsson, J. Wargo, 2020, Nature.

Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer

S. H. van der Burg, L. Olsen, B. Nelson, 2020, Oncotarget.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

M. Ringnér, M. Lauss, M. Donia, 2017, Nature Communications.

Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes

Z. Szallasi, A. Eklund, N. McGranahan, 2016, Nature Biotechnology.

Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know

M. Donia, I. Svane, S. Heegaard, 2020, International journal of molecular sciences.

Predictors of responses to immune checkpoint blockade in advanced melanoma

David M. Woods, Y. Koguchi, G. Kroemer, 2017, Nature Communications.

In-chip fabrication of free-form 3D constructs for directed cell migration analysis.

Mark Holm Olsen, Morten Hansen, I. Svane, 2013, Lab on a chip.

Efficient large volume electroporation of dendritic cells through micrometer scale manipulation of flow in a disposable polymer chip

I. Svane, D. Selmeczi, N. Larsen, 2011, Biomedical microdevices.

Characterization of Monocyte‐Derived Dendritic Cells Maturated With IFN‐α

I. Svane, M. Claesson, A. Pedersen, 2006, Scandinavian journal of immunology.

Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations

Z. Szallasi, A. Eklund, M. Donia, 2020, Frontiers in Immunology.

Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions

M. Donia, I. Svane, Ö. Met, 2022, Expert opinion on biological therapy.

Principles of adoptive T cell therapy in cancer

M. Donia, I. Svane, Ö. Met, 2018, Seminars in Immunopathology.

Spontaneous presence of FOXO3-specific T cells in cancer patients

I. Svane, Ö. Met, P. Straten, 2014, Oncoimmunology.

Expression of β2‐microglobulin by premalignant epithelium

I. Svane, B. Petersen, O. Brændstrup, 1993 .

BRAF inhibition improves tumor recognition by the immune system

M. Donia, I. Svane, P. Fagone, 2012, Oncoimmunology.

Dissection of T-cell antigen specificity in human melanoma.

T. Schumacher, M. Donia, I. Svane, 2012, Cancer research.

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA‐DR−/low Myeloid‐Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

H. Johnsen, I. Svane, A. Vangsted, 2010, Scandinavian journal of immunology.

Therapeutic Vaccination against A Modified Minimal Survivin Epitope Induces Functional CD4 T Cells That Recognize Survivin‐Expressing Cells

I. Svane, O. Met, M. Andersen, 2016, Scandinavian journal of immunology.

Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot

I. Svane, P. Straten, S. K. Larsen, 2012, Cells.

Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient

I. Svane, S. Hadrup, P. thor Straten, 2007, Cancer Immunology, Immunotherapy.

Immunogenicity of Bcl-2 in patients with cancer.

J. Becker, E. Balslev, I. Svane, 2005, Blood.

Design and validation of conditional ligands for HLA‐B*08:01, HLA‐B*15:01, HLA‐B*35:01, and HLA‐B*44:05

I. Svane, M. Heemskerk, M. Heemskerk, 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion

M. Donia, I. Svane, S. Hadrup, 2012, Cancer Immunology and Immunotherapy.

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

M. Donia, I. Svane, H. Hendel, 2016, Clinical Cancer Research.

Analysis of survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA.

I. Svane, O. Met, 2013, Methods in molecular biology.

Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition.

M. Donia, I. Svane, H. Sengeløv, 2021, Cytotherapy.

An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma

I. Svane, A. O. Gang, Ö. Met, 2021, OncoImmunology.

Interferon‐α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F‐positive essential thrombocythemia and polycythemia vera

I. Svane, M. Jensen, H. Hasselbalch, 2016, European journal of haematology.

Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion.

M. Donia, I. Svane, P. Straten, 2013, The Journal of investigative dermatology.

Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer.

I. Svane, L. Sengeløv, H. Lindberg, 2016, Clinical genitourinary cancer.

Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

H. Johnsen, S. Buus, I. Svane, 2004, Cancer Immunology, Immunotherapy.

Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)

S. Brunak, I. Svane, B. Jensen, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort.

A. Hrõbjartsson, H. Schmidt, L. Bastholt, 2019, European journal of cancer.

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.

I. Svane, S. Hadrup, A. Berntsen, 2010, Cytotherapy.

Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial

H. Schmidt, I. Svane, G. Cook, 2010, Clinical Cancer Research.

Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma: A Clinical Phase 1/2 trial

I. Svane, M. Claesson, A. Berntsen, 2008, Journal of immunotherapy.

Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment

I. Svane, Ö. Met, M. Carretta, 2022, Oncoimmunology.

Title: Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen

M. Donia, I. Svane, H. Hendel, 2016 .

Characterization of Ex Vivo Expanded Tumor Infiltrating Lymphocytes from Patients with Malignant Melanoma for Clinical Application

I. Svane, P. thor Straten, M. Andersen, 2011, Journal of skin cancer.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

R. Dummer, E. Rozeman, H. Schmidt, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma

M. Donia, I. Svane, S. Hadrup, 2017, Oncotarget.

PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer

M. Donia, I. Svane, S. Ott, 2017, Clinical Cancer Research.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

B. Seliger, T. Schumacher, M. V. van Buuren, 2017, Cancer research.

Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients

L. Bastholt, I. Svane, S. Hadrup, 2013, Oncoimmunology.

Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes

M. Donia, I. Svane, P. Straten, 2012, Oncoimmunology.

Cancer Vaccines and the Potential Benefit of Combination with Standard Cancer Therapies

I. Svane, M. Andersen, E. Ellebaek, 2013 .

Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFÎ2-expressing cancer cells in a TGFÎ2-dependent manner

M. Donia, I. Svane, R. Mortensen, 2021 .

Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses - implications for the management of irAEs

M. Donia, I. Svane, T. Borch, 2018, bioRxiv.

Cancer immunotherapy in patients with brain metastases

M. Donia, I. Svane, T. Borch, 2018, Cancer Immunology, Immunotherapy.

Differential effects of corticosteroids and anti‐TNF on tumor‐specific immune responses: implications for the management of irAEs

M. Donia, I. Svane, T. Borch, 2019, International journal of cancer.

Frequent adaptive immune responses against arginase-1

M. Donia, I. Svane, R. Mortensen, 2018, Oncoimmunology.

PD‐L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy

M. Dolled-Filhart, K. Emancipator, H. Schmidt, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine

M. Donia, I. Svane, T. Borch, 2016, Oncoimmunology.

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway

I. Svane, S. K. Larsen, M. Andersen, 2014, Leukemia.

Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types

I. Svane, U. Lassen, M. Hansen, 2021, Frontiers in Oncology.

The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56.

S. R. Pedersen, I. Svane, P. thor Straten, 2021, Cytotherapy.

Influence of Metronomic Cyclophosphamide and Interleukine-2 alone or Combined on Blood Regulatory T Cells in Patients with Advanced Malignant Melanoma Treated with Dendritic Cell Vaccines

I. Svane, P. Straten, M. Andersen, 2012 .

Increase of Circulating CD4+CD25highFoxp3+ Regulatory T Cells in Patients With Metastatic Renal Cell Carcinoma During Treatment With Dendritic Cell Vaccination and Low-Dose Interleukin-2

I. Svane, A. Berntsen, P. Straten, 2010, Journal of immunotherapy.

Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.

I. Svane, A. Pedersen, K. Nikolajsen, 2008, Vaccine.

MHC class II-bound self-peptides can be effectively separated by isoelectric focusing and bind optimally to their MHC class II restriction elements around pH 5.0.

I. Svane, I. Svendsen, A. Engel, 1994, Immunology.

Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

I. Svane, M. Andersen, S. M. Ahmad, 2019, Cancer Immunology, Immunotherapy.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

P. Ascierto, R. Fisher, A. Ribas, 2019, Nature Medicine.

Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma

H. Johnsen, I. Svane, M. Brimnes, 2006, Clinical and experimental immunology.

Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an HLA-A2-restricted epitope derived from indoleamine 2,3 dioxygenase

I. Svane, R. Andersen, P. Straten, 2013, Journal of Immunotherapy for Cancer.

Cancer Therapy : Clinical Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2 , 3 Dioxygenase

I. Svane, R. Andersen, P. Straten, 2013 .

HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.

M. Donia, I. Svane, T. Klausen, 2013, Cancer research.

Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

I. Svane, R. Andersen, P. thor Straten, 2013, Clinical Cancer Research.

Characterization of T-cell responses against IκBα in cancer patients

I. Svane, T. M. Frøsig, M. Hansen, 2012, Oncoimmunology.

The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase

J. Becker, T. Schumacher, I. Svane, 2009, PloS one.

Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients.

J. Becker, I. Svane, P. thor Straten, 2009, The Journal of clinical investigation.

The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines

J. Becker, I. Svane, P. thor Straten, 2009, Cancer Immunology, Immunotherapy.

RhoC a new target for therapeutic vaccination against metastatic cancer

I. Svane, P. thor Straten, M. Andersen, 2008, Cancer Immunology, Immunotherapy.

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

D. Schadendorf, P. Ascierto, M. Smylie, 2020, Journal for immunotherapy of cancer.

Tumors developing in nude mice express unusually large amounts of MHC class I antigens

I. Svane, B. Petersen, H. Juul-Madsen, 1991, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

M. Karsdal, H. Schmidt, I. Svane, 2018, Journal of Immunotherapy for Cancer.

Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.

I. Svane, L. Sengeløv, T. Borch, 2017, Cytotherapy.

Clinical Impact of the Number of Treatment Cycles in First‐Line Docetaxel for Patients With Metastatic Castration‐Resistant Prostate Cancer

I. Svane, H. Lindberg, P. Kongsted, 2017, Clinical genitourinary cancer.

Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer

I. Svane, L. Sengeløv, R. Bisbjerg, 2016, Anti-cancer drugs.

Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit?

I. Svane, L. Sengeløv, G. Daugaard, 2015, Urologic oncology.

P069 Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer. Is there a clinical benefit?

I. Svane, L. Sengeløv, G. Daugaard, 2014 .

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study

M. Donia, H. Schmidt, L. Bastholt, 2021, Cancers.

The controversial role of TNF in melanoma

M. Donia, I. Svane, J. Kjeldsen, 2016, Oncoimmunology.

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells

I. Svane, M. Andersen, S. Munir, 2013, Oncoimmunology.

The Immunogenicity of the hTERT540-548 Peptide in Cancer

I. Svane, L. Sengeløv, P. thor Straten, 2008, Clinical Cancer Research.

Silencing of the glucocorticoid-induced leucine zipper improves the immunogenicity of clinical-grade dendritic cells.

I. Svane, Ö. Met, D. Cathelin, 2013, Cytotherapy.

MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

J. Becker, L. Rasmussen, M. Donia, 2019, Cancer Immunology Research.

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma

Z. Szallasi, I. Csabai, M. Lauss, 2020, Cancers.

Immunotherapy for metastatic colorectal cancer: Present status and new options

I. Svane, P. Straten, M. Andersen, 2012, Scandinavian journal of gastroenterology.

High MHC class I expression correlates with slow growth in UV‐induced skin carcinomas in hairless mice

I. Svane, H. Wulf, A. Engel, 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

The Susceptibility to Cytotoxic T Lymphocyte Mediated Lysis of Chemically Induced Sarcomas from Immunodeficient and Normal Mice

I. Svane, A. Thomsen, A. Engel, 1997, Scandinavian journal of immunology.

Molecular aberrations in the MHC class I‐restricted pathway for antigen presentation in methylcholanthrene sarcomas from nude mice: discrepancies between MHC mRNA and surface protein

I. Svane, M. Madsen, M. Pedersen, 1997, Clinical and experimental immunology.

Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive transfer with tumor-infiltrating lymphocytes in melanoma

Z. Szallasi, M. Donia, I. Svane, 2021 .

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients

M. Donia, I. Svane, T. Borch, 2014, Journal of Immunotherapy for Cancer.

Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial.

I. Svane, N. Abildgaard, L. Knudsen, 2016, Stem cell investigation.

Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer

J. Becker, I. Svane, Ö. Met, 2015, Oncoimmunology.

Bearing Extremely Low-Affinity TCRs Multimers Reveals Functional T Cells MHC - Antibody Stabilization of Peptide

M. Donia, I. Svane, A. Sewell, 2014 .

Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function.

I. Svane, O. Met, A. Pedersen, 2009, Vaccine.

Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab

H. Schmidt, I. Svane, K. Fode, 2016, Oncoimmunology.

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression

M. Donia, I. Svane, L. Hölmich, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma

I. Svane, T. Borch, Ö. Met, 2016, Oncoimmunology.

Impaired circulating myeloid DCs from myeloma patients.

H. Johnsen, I. Svane, T. Do, 2004, Cytotherapy.

Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor‐induced colitis

M. Donia, I. Svane, J. Seidelin, 2022, Alimentary pharmacology & therapeutics.

The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study.

L. Køber, I. Svane, C. Torp-Pedersen, 2020, European heart journal.

Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors.

I. Svane, E. Ellebaek, Nicole A Romanski, 2020, European journal of cancer.

Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab

I. Svane, R. Andersen, P. Norgaard, 2014, Oncoimmunology.

The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients.

M. Donia, H. Schmidt, L. Bastholt, 2021, Cancer epidemiology.

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

M. Donia, H. Schmidt, L. Bastholt, 2019, Cancers.

Cancer immunotherapy in patients with preexisting autoimmune disorders

M. Donia, I. Svane, M. Pedersen, 2017, Seminars in Immunopathology.

Isolated asymptomatic masseter muscle metastasis as first sign of metastatic disease in a patient with known melanoma

I. Svane, Caroline A Gjorup, H. Hendel, 2016 .

Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

I. Svane, M. Pedersen, P. thor Straten, 2014, Cancer Immunology, Immunotherapy.

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals

I. Svane, H. Hasselbalch, C. Ellervik, 2019, Blood Cancer Journal.

Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes

I. Svane, H. Hasselbalch, M. Thomassen, 2018, Leukemia & lymphoma.

Vaccination with Wild-Type p53 Peptide Pulsed-Dendritic Cells in Patients with Advanced Breast Cancer. Results from a Phase II Study

H. Johnsen, I. Svane, M. Claesson, 2004 .

The real-world impact of modern treatments on the survival of patients with metastatic melanoma.

M. Donia, H. Schmidt, L. Bastholt, 2019, European journal of cancer.

Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

Tamara J Laskowski, J. Taube, P. Ascierto, 2022, Journal of Translational Medicine.

Spontaneous T-cell responses against peptides derived from the Taxol resistance–associated gene-3 (TRAG-3) protein in cancer patients

J. Becker, I. Svane, P. Straten, 2005, Cancer Immunology, Immunotherapy.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

R. Dummer, E. Rozeman, H. Schmidt, 2019 .

Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO)

E. Rozeman, C. Blank, H. Schmidt, 2016 .

Immune check point inhibitors are associated with a spectrum of cardiac events in patients with cancer.

I. Svane, G. Gislason, M. Schou, 2021, European heart journal.

Immunoprofiles of colorectal cancer from Lynch syndrome

I. Svane, G. Jönsson, A. Langkilde, 2018, Oncoimmunology.

Clinical value of routine [18F]2‐fluoro‐2‐deoxy‐d‐glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma

M. Donia, I. Svane, H. Hendel, 2023, International journal of cancer.

Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

I. Svane, J. Haanen, Ö. Met, 2022, The Lancet Oncology.

Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2.

I. Svane, P. Straten, R. Andersen, 2011, Cancer research.

The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro

M. Donia, I. Svane, M. Westergaard, 2020, Cancer Immunology, Immunotherapy.

Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.

I. Svane, A. Berntsen, O. Met, 2008, Vaccine.

Indoleamine 2,3-dioxygenase vaccination

I. Svane, M. Andersen, 2015, Oncoimmunology.

Brief report Increase in circulating CD4 (cid:1) CD25 (cid:1) Foxp3 (cid:1) T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN- (cid:2)

I. Svane, M. Jensen, H. Hasselbalch, 2011 .

B‐cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon‐α2, or combination treatment

I. Svane, H. Hasselbalch, C. Nielsen, 2019, European journal of haematology.

Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response

I. Svane, H. Hasselbalch, M. Holmström, 2018, Oncoimmunology.

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial

I. Svane, E. Ehrnrooth, M. Andersen, 2022, Frontiers in Immunology.

Cell culture plastics with immobilized interleukin-4 for monocyte differentiation.

I. Svane, N. Larsen, M. Jakobsen, 2011, Journal of biomedical materials research. Part A.

Effect of Subcutaneous Human rleukin-21 in Patients with Metastatic Melanoma or R al Cell Carcinoma : A Phase I Trial

I. Svane, P. Selby, Janet E Brown, 2010 .

Real-world data on melanoma brain metastases and survival outcome

S. Møller, M. Donia, I. Svane, 2022, Melanoma research.

Clinical application of dendritic cells in cancer vaccination therapy

H. Johnsen, S. Buus, I. Svane, 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

M. Donia, I. Svane, Ö. Met, 2018, Oncoimmunology.

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial

L. Olsen, I. Svane, T. Klausen, 2020, Frontiers in Immunology.

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

D. Karlis, G. Coukos, U. Dafni, 2019 .

Immune Responses in Patients with Metastatic Renal Cell Carcinoma Treated with Dendritic Cells Pulsed with Tumor Lysate

I. Svane, A. Berntsen, A. Pedersen, 2009, Scandinavian journal of immunology.

PD-L1 specific tumor infiltrating lymphocytes occur frequently in melanoma and HNSCC patients.

M. Donia, I. Svane, R. Andersen, 2014 .

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV

I. Svane, Ö. Met, C. Niemann, 2022, Frontiers in Oncology.

Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor‐induced colitis—authors' reply

M. Donia, I. Svane, J. Seidelin, 2022, Alimentary pharmacology & therapeutics.

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

W. V. van Harten, T. Schumacher, J. Beijnen, 2022, The New England journal of medicine.

Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).

M. Donia, I. Svane, E. Høgdall, 2022, European journal of cancer.

Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy

C. Johansen, H. Schmidt, I. Svane, 2023, Acta oncologica.

Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2.

I. Svane, Ö. Met, P. thor Straten, 2016, Methods in molecular biology.

Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review.

I. Svane, C. Zachariae, A. Simonsen, 2020, Journal of the American Academy of Dermatology.

The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.

I. Svane, M. Andersen, T. Z. Iversen, 2015, Basic & clinical pharmacology & toxicology.

T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road

I. Svane, Ö. Met, M. Crowther, 2020, Cells.

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model

M. Donia, I. Svane, J. Nilsson, 2017, Nature Communications.

HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.

M. Donia, I. Svane, O. Nilsson, 2019, Cancer research.

ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors

I. Svane, Ö. Met, C. Chamberlain, 2021, Immuno.

Efficacy of Adoptive Therapy with Tumor-infiltrating Lymphocytes and Recombinant Interleukin-2 in Advanced Cutaneous Melanoma: A Systematic Review and Meta-analysis.

D. Karlis, G. Coukos, U. Dafni, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

D. Schadendorf, P. Ascierto, M. Smylie, 2017, The Lancet. Oncology.

Genome-wide CRISPR-Cas9 Screening Reveals Ubiquitous T cell Cancer Targeting via the monomorphic MHC class I related protein MR1

M. Donia, I. Svane, A. Sewell, 2019, Nature Immunology.

Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types

M. Karsdal, J. Erler, J. Aerts, 2022, Cellular and Molecular Life Sciences.

Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade

M. Karsdal, H. Schmidt, I. Svane, 2020, Cancers.

Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

I. Svane, P. thor Straten, M. Andersen, 2008, Cancer Immunology, Immunotherapy.

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

D. Schadendorf, H. Olsson, J. Wargo, 2020, Nature.

Tumor‐infiltrating lymphocytes for the treatment of metastatic cancer

M. Donia, I. Svane, J. Haanen, 2015, Molecular oncology.

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

G. Coukos, M. Donia, I. Svane, 2019, British Journal of Cancer.

Broadening the repertoire of melanoma-associated T-cell epitopes

M. Donia, I. Svane, S. Hadrup, 2015, Cancer Immunology, Immunotherapy.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

D. Schadendorf, P. Ascierto, M. Smylie, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antibody Stabilization of Peptide–MHC Multimers Reveals Functional T Cells Bearing Extremely Low-Affinity TCRs

M. Donia, I. Svane, A. Sewell, 2014, The Journal of Immunology.

Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.

M. Donia, I. Svane, P. Fagone, 2015, Cancer research.

Escape from nonsense-mediated decay associates with anti-tumor immunogenicity

A. Rowan, C. Swanton, S. Quezada, 2019, Nature Communications.

Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.

I. Svane, U. Lassen, A. Borch, 2020, Cytotherapy.

Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma

M. Donia, I. Svane, M. Pedersen, 2015, Human vaccines & immunotherapeutics.

Effector and Regulatory T Cells in Patients with Acute Optic Neuritis

I. Svane, J. Frederiksen, N. Grigoriadis, 2012, Neuroimmunomodulation.

B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?

M. Lauss, M. Donia, I. Svane, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Long-Term Exposure to Inflammation Induces Differential Cytokine Patterns and Apoptosis in Dendritic Cells

I. Svane, M. Hansen, A. Obers, 2019, Front. Immunol..

Studies on mRNA Electroporation of Immature and Mature Dendritic Cells: Effects on their Immunogenic Potential

I. Svane, Ö. Met, J. Eriksen, 2008, Molecular biotechnology.

Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.

Santiago J. Carmona, P. Sorger, M. Delorenzi, 2021, Cancer cell.

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies

I. Svane, M. Holmström, M. Andersen, 2018, Front. Immunol..

Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens

Z. Szallasi, I. Csabai, M. Lauss, 2021, Frontiers in Immunology.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

D. Schadendorf, K. Savage, P. Ascierto, 2019, JAMA oncology.

The Universal Character of the Tumor-Associated Antigen Survivin

J. Becker, I. Svane, P. Straten, 2007, Clinical Cancer Research.

Collagen density regulates the activity of tumor-infiltrating T cells

L. Grøntved, M. Donia, I. Svane, 2018, Journal of Immunotherapy for Cancer.

Feasibility of Intratumoral Anti-PD1 as Treatment of Human Basal Cell Carcinoma: An Explorative Study with Adjuvant Ablative Fractional Laser

I. Svane, M. Hædersdal, S. H. Omland, 2022, Cancers.

Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma

I. Svane, E. Wenande, U. H. Olesen, 2021, Cancers.

Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer

M. Anglesio, L. Olsen, B. Nelson, 2020, Cancers.

Transcriptomic signatures of tumors undergoing T cell attack

Z. Szallasi, I. Csabai, M. Lauss, 2021, Cancer Immunology, Immunotherapy.

Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

Tamara J Laskowski, J. Taube, P. Ascierto, 2022, Journal of translational medicine.

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial

I. Svane, H. Hasselbalch, R. Mortensen, 2023, Frontiers in Immunology.

Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies.

M. Donia, I. Svane, M. Andersen, 2015, Drug discovery today.

HLA‐B35‐restricted immune responses against survivin in cancer patients

J. Becker, I. Svane, P. Straten, 2004, International journal of cancer.

Identification of Novel Survivin-Derived CTL Epitopes with Different HLA-A-Restriction Profiles

Mads Hald Andersen, Jürgen C. Becker, J. Becker, 2004, Cancer biology & therapy.

A survivin specific T-cell clone from a breast cancer patient displays universal tumor cell lysis

I. Svane, P. Straten, M. Andersen, 2008, Cancer biology & therapy.

CD8 T-cell Responses against Cyclin B1 in Breast Cancer Patients with Tumors Overexpressing p53

E. Balslev, I. Svane, S. Hadrup, 2009, Clinical Cancer Research.

The Targeting of IDO-Mediated Immune Escape in Cancer

I. Svane, M. Andersen, T. Z. Iversen, 2014 .

More tricks with tetramers: a practical guide to staining T cells with peptide–MHC multimers

Mark Peakman, M. Donia, I. Svane, 2015, Immunology.

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

M. Donia, L. Bastholt, I. Svane, 2018, Oncoimmunology.

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

P. Ascierto, A. Ribas, H. Schmidt, 2020, Journal for ImmunoTherapy of Cancer.

Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma

M. Donia, H. Schmidt, L. Bastholt, 2020, Cancers.

University of Southern Denmark Improved progression-free long-term survival of a nation-wide patient population with metastatic melanoma Soerensen,

M. Donia, H. Schmidt, L. Bastholt, 2020 .

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.

H. Schmidt, L. Bastholt, I. Svane, 2019, European journal of cancer.

Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study

B. Nelson, M. Donia, I. Svane, 2018, Oncoimmunology.

Neuroprotective and anti‐inflammatory mechanisms are activated early in Optic Neuritis

I. Svane, J. Frederiksen, N. Grigoriadis, 2015, Acta neurologica Scandinavica.

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.

I. Svane, S. Hadrup, P. thor Straten, 2011, Blood.

Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase

M. Donia, I. Svane, T. Klausen, 2012, PloS one.

Methylcholanthrene‐induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression

I. Svane, J. Clausen, J. Rygaard, 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor.

M. Donia, I. Svane, O. Met, 2014, Cytotherapy.

Antigen‐Specific T‐Cell Immunity in Multiple Myeloma Patients is Restored Following High‐Dose Therapy: Implications for Timing of Vaccination

H. Johnsen, I. Svane, K. Nikolajsen, 2007, Scandinavian journal of immunology.

Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes

I. Svane, L. Vinner, A. Fomsgaard, 2009, AIDS.

Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.

I. Svane, A. Berntsen, P. Geertsen, 2006, European urology.

Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers

H. Johnsen, E. Balslev, I. Svane, 2007, Cancer Immunology, Immunotherapy.

Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.

C. von Buchwald, I. Svane, M. Therkildsen, 2011, Cytotherapy.

Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner

M. Donia, I. Svane, R. Mortensen, 2021, Cellular & Molecular Immunology.

Peptide–MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations

Andrew K. Sewell, Mark Peakman, Barbara Szomolay, 2018, The Journal of Immunology.

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

I. Svane, S. Koschmieder, H. Hasselbalch, 2021, Frontiers in Oncology.

In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

I. Svane, M. Westergaard, M. Nielsen, 2020, Cancer Immunology, Immunotherapy.

LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations

D. Schadendorf, P. Ascierto, R. Dummer, 2017 .

Wildtype p53-specific Antibody and T-Cell Responses in Cancer Patients

S. Justesen, S. Buus, M. Harndahl, 2011, Journal of immunotherapy.

Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study

I. Svane, L. Skov, C. Zachariae, 2021, Cancers.

Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice

H. Ljunggren, I. Svane, J. Rygaard, 1996, European journal of immunology.

LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial

I. Svane, J. Haanen, Ö. Met, 2022, Annals of Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting

I. Svane, A. Christensen, B. Zerahn, 2021, Acta oncologica.

The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials.

M. Donia, H. Schmidt, L. Bastholt, 2017, European journal of cancer.

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

M. Donia, I. Svane, H. Hendel, 2021, Nature Medicine.

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

M. Donia, I. Svane, H. Hendel, 2021, Nature Medicine.

Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial

I. Svane, I. Dufva, K. Grønbæk, 2021, Cancer Immunology, Immunotherapy.

Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report

I. Svane, M. Andersen, A. Mellemgaard, 2018, Front. Immunol..

The Danish Melanoma Database

H. Schmidt, I. Svane, H. Lorentzen, 2016, Clinical epidemiology.

Therapeutic Cancer Vaccines in Combination with Conventional Therapy

Mads Hald Andersen, I. Svane, P. thor Straten, 2010, Journal of biomedicine & biotechnology.

LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma.

I. Svane, M. Nielsen, O. Rekdal, 2022, Journal of Clinical Oncology.

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf Kinase inhibitory protein.

J. Ragoussis, L. Heinzerling, C. Figdor, 2017, Oncotarget.

Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients.

I. Svane, S. Hadrup, P. Kvistborg, 2008, Human immunology.

Principles of adoptive T cell therapy in cancer

M. Donia, I. Svane, Ö. Met, 2018, Seminars in Immunopathology.

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

Thomas M Froesig, I. Svane, S. Hadrup, 2012, Cancer Immunology, Immunotherapy.

Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?

I. Svane, E. Verdegaal, Inge Marie Svane, 2014, Cancer Immunology, Immunotherapy.

Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma

Z. Szallasi, M. Donia, I. Svane, 2021, The Journal of clinical investigation.

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy

M. Donia, I. Svane, A. Kverneland, 2022, Molecular therapy oncolytics.

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein

J. Ragoussis, L. Heinzerling, C. Figdor, 2017, Oncotarget.

Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma

D. Schadendorf, H. Olsson, J. Wargo, 2020, Nature.

High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer

H. Flyger, E. Balslev, I. Svane, 2010, Breast Cancer Research and Treatment.

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

M. Donia, I. Svane, S. Hadrup, 2012, Journal of Translational Medicine.

The real‐world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

M. Donia, H. Schmidt, L. Bastholt, 2019, International journal of cancer.

Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma

M. Donia, I. Svane, S. Hadrup, 2013, Journal of Immunotherapy for Cancer.

Characterization and Comparison of ‘Standard’ and ‘Young’ Tumour‐Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution

M. Donia, I. Svane, M. Donia, 2012, Scandinavian journal of immunology.

Checkpoint inhibitors in breast cancer - Current status.

I. Svane, M. Andersson, D. Nielsen, 2018, Cancer treatment reviews.

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

A. Hauschild, S. Puig, R. Fisher, 2021, European journal of cancer.

Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.

P. Ascierto, A. Ribas, H. Schmidt, 2022, Journal of Clinical Oncology.

Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma.

I. Svane, M. Andersen, N. J. Nitschke, 2017, Stem cell investigation.

Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.

I. Svane, M. Andersen, N. J. Nitschke, 2016, Cytotherapy.

Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells

M. Zacharias, M. Donia, I. Svane, 2019, Science Immunology.

T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy

B. Seliger, M. Donia, I. Svane, 2018, Cancer Immunology Research.

Cancer treatment: the combination of vaccination with other therapies

J. Becker, I. Svane, D. Schrama, 2008, Cancer Immunology, Immunotherapy.

CD8+ T cells are crucial for the ability of congenic normal mice to reject highly immunogenic sarcomas induced in nude mice with 3‐methylcholanthrene

I. Svane, A. Engel, O. Werdelin, 2000, Clinical and experimental immunology.

CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment

M. Donia, I. Svane, T. Klausen, 2016, Oncoimmunology.

Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures.

I. Svane, P. Kvistborg, P. Straten, 2012, Cellular immunology.

Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors

J. Becker, I. Svane, P. thor Straten, 2010, Cancer Immunology, Immunotherapy.

First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer

M. Donia, I. Svane, S. Hadrup, 2023, Frontiers in Immunology.

A promiscuous survivin-derived T-cell epitope restricted to the HLA-A3 super-type alleles.

I. Svane, P. Kvistborg, P. Straten, 2012, The Journal of investigative dermatology.

T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients

I. Svane, A. Bentzen, S. Hadrup, 2019, Oncoimmunology.

Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy.

M. Donia, I. Svane, N. Larsen, 2013, Vaccine.

FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma

I. Svane, H. Johannesen, H. Hendel, 2012, Cancer Immunology, Immunotherapy.

Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma

M. Donia, I. Svane, J. Kringelum, 2022, Oncoimmunology.

Next-generation detection of antigen-responsive T cells using DNA barcode-labeled MHC-I 1 multimers

Z. Szallasi, A. Eklund, C. Swanton, 2016 .

Adoptive T-cell therapy (ACT) with TILs for metastatic melanoma: Clinical responses and durable persistence of anticancer responses in peripheral blood.

M. Donia, I. Svane, R. Andersen, 2013 .

Peptide Super-Agonist Enhances T-Cell Responses to Melanoma

M. Donia, I. Svane, A. Sewell, 2019, Front. Immunol..

Manufacture of adoptive cell therapies at academic cancer centers: Scientific, safety and regulatory challenges.

F. André, I. Svane, K. Saini, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune Monitoring Using mRNA-Transfected Dendritic Cells.

I. Svane, Ö. Met, T. H. Borch, 2016, Methods in molecular biology.

Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients

C. Johansen, L. Bastholt, I. Svane, 2023, Annals of Surgical Oncology.

Immune Checkpoint Inhibitor Treatment and Ophthalmologist Consultations in Patients with Malignant Melanoma or Lung Cancer—A Nationwide Cohort Study

C. Torp‐Pedersen, I. Svane, M. Schou, 2021, Cancers.

Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21.

M. Rosenkilde, I. Svane, N. Larsen, 2016, Cytotherapy.

Acute and Late Toxicity Following Adjuvant High-Dose Chemotherapy for High-Risk Primary Operable Breast Cancer A Quality Assessment Study

H. Johnsen, I. Svane, S. W. Hansen, 2002, Acta oncologica.

Exhaustion of Human Dendritic Cells Results in a Switch from the IL-15R/IL-15- to IL-2R/IL-2-driven Expansion of Antigen-specific CD8+ T Cells

I. Svane, P. Kalinski, N. Obermajer, 2016, The Journal of Immunology.

Expansion of circulating CD56bright natural killer cells in patients with JAK2‐positive chronic myeloproliferative neoplasms during treatment with interferon‐α

I. Svane, M. Jensen, H. Hasselbalch, 2015, European journal of haematology.

Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.

I. Svane, M. Jensen, H. Hasselbalch, 2011, Blood.

Combination therapy with immune check point inhibitors and acute kidney injury

I. Svane, A. Møller, E. Gravesen, 2023, Acta oncologica.

Differential ultracentrifugation enables deep plasma proteomics through enrichment of extracellular vesicles

Kristina B. Emdal, J. Olsen, I. Svane, 2022, Proteomics.

Real-world evidence to guide healthcare policies in oncology

M. Donia, I. Svane, S. W. Hansen, 2019, Oncotarget.

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines

I. Svane, Ö. Met, M. Carretta, 2020, Oncoimmunology.

Confinement dependent chemotaxis in two-photon polymerized linear migration constructs with highly definable concentration gradients

I. Svane, N. Larsen, M. Olsen, 2015, Biomedical microdevices.

Cellular based cancer vaccines: type 1 polarization of dendritic cells.

I. Svane, Ö. Met, M. Hansen, 2012, Current medicinal chemistry.

KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma.

P. Ascierto, N. Ibrahim, A. Ribas, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.

I. Svane, L. Jensen, Kevin Lim, 2021, Gynecologic Oncology.

Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy

A. Eklund, I. Svane, S. Hadrup, 2023, Frontiers in Genetics.

CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer

M. Donia, K. Harbst, I. Svane, 2020, Scientific Reports.

Peripheral memory T cells specific for Arginase-1

I. Svane, M. Andersen, S. M. Ahmad, 2019, Cellular & Molecular Immunology.

Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol

I. Svane, G. Persson, H. Hendel, 2023, BMJ Open.

Genome-wide CRISPR-Cas9 Screening Reveals Ubiquitous T cell Cancer Targeting via the monomorphic MHC class I related protein MR1

M. Donia, I. Svane, A. Sewell, 2019, Nature Immunology.

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

M. Donia, I. Svane, S. Hadrup, 2012, Journal of Translational Medicine.

778 Modulating tumor microenvironment with arginase-1 specific T cells

I. Svane, Ö. Met, M. Holmström, 2021, Journal for ImmunoTherapy of Cancer.

The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity

I. Svane, M. Andersen, S. M. Ahmad, 2014, Blood Cancer Journal.

Partially differentiated polyfunctional T cells dominate the periphery after tumor-infiltrating lymphocytes therapy for cancer

M. Donia, I. Svane, S. Ott, 2016 .

Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: Implications for the management of irAEs

M. Donia, I. Svane, C. Chamberlain, 2018, Annals of Oncology.

EUMelaReg: A European platform for outcome research on real world treatment data of patients with advanced melanoma.

M. Weichenthal, D. Schadendorf, H. Schmidt, 2018, Annals of Oncology.

Letter: be careful of gastrointestinal CMV infection in adverse event from ICIs therapy in solid tumours—Authors' reply

M. Donia, I. Svane, J. Seidelin, 2023, Alimentary pharmacology & therapeutics.

Increased immunopotency of monocyte derived dendritic cells from patients with optic neuritis is inhibited in vitro by simvastatin

I. Svane, J. Frederiksen, A. Tsakiri, 2010, Experimental Neurology.

Seasonal variation in effect of anti‐PD‐1 initiation on overall survival among patients with advanced melanoma

M. Donia, H. Schmidt, L. Bastholt, 2022, Pigment Cell & Melanoma Research.

Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report

I. Svane, J. Seidelin, M. Helms, 2022, BMJ open gastroenterology.

14PDExpansion of tumor specific tumor-infiltrating lymphocytes (TIL) from sarcoma and the potential benefit of anti-CD137 stimulation: A prerequisite for adoptive cell transfer (ACT) immunotherapy

I. Svane, M. Westergaard, M. Nielsen, 2017 .

54PDPreclinical development of tumor-infiltrating lymphocytes (TILs) based adoptive cell transfer immunotherapy (ACT) for patients with advanced ovarian cancer

M. Donia, I. Svane, M. Westergaard, 2016 .

Preclinical development of tumor-infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma

I. Svane, M. Nielsen, A. Krarup-Hansen, 2016 .

Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511).

P. Ascierto, M. Smylie, I. Svane, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA48 Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial

I. Svane, M. Andersen, E. Martinenaite, 2020 .

Restoring tumor immunogenicity with dendritic cell reprogramming

M. Höglund, I. Svane, C. Pereira, 2023, Science Immunology.

Efficacy and safety of IO103 a novel anti PD-L1 vaccine in basal cell carcinoma.

I. Svane, L. Skov, C. Zachariae, 2020, Journal of Clinical Oncology.

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma

M. Donia, I. Svane, S. Hadrup, 2018, Oncotarget.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

D. Schadendorf, P. Ascierto, M. Smylie, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

M. Donia, H. Schmidt, L. Bastholt, 2019, Cancers.

Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma

D. Schadendorf, H. Olsson, J. Wargo, 2020, Nature.

Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.

R. Scolyer, E. Rozeman, C. Blank, 2019, Journal of Clinical Oncology.

Interferon‐γ‐Induced MHC Class I Expression and Defects in Jak/Stat Signalling in Methylcholanthrene‐Induced Sarcomas

I. Svane, A. Engel, O. Werdelin, 1997, Scandinavian journal of immunology.

MCA Sarcomas Induced in scid Mice are More Immunogenic than MCA Sarcomas Induced in Congenic, Immunocompetent Mice

I. Svane, J. Rygaard, A. Engel, 1997, Scandinavian journal of immunology.

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

M. Donia, I. Svane, S. Hadrup, 2023, Frontiers in Immunology.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

Changes in Peripheral Blood Level of Regulatory T cells in Patients with Malignant Melanoma During Treatment with Dendritic Cell Vaccination and Low‐dose IL‐2

I. Svane, P. Straten, M. Brimnes, 2011, Scandinavian journal of immunology.

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

I. Svane, S. Hadrup, M. Andersen, 2012, Cancer Immunology, Immunotherapy.

Confinement dependent chemotaxis in two-photon polymerized linear migration constructs with highly definable concentration gradients

I. Svane, N. Larsen, M. Olsen, 2015, Biomedical Microdevices.

Characterization of Ex Vivo Expanded Tumor Infiltrating Lymphocytes from Patients with Malignant Melanoma for Clinical Application

I. Svane, P. thor Straten, M. Andersen, 2011, Journal of skin cancer.

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein

J. Ragoussis, D. Cavalieri, I. Svane, 2017, Oncotarget.

Large-Scale mRNA Transfection of Dendritic Cells by Electroporation in Continuous Flow Systems.

I. Svane, D. Selmeczi, Ö. Met, 2016, Methods in molecular biology.

Effector and Regulatory T Cells in Patients with Acute Optic Neuritis

I. Svane, J. Frederiksen, N. Grigoriadis, 2012, Neuroimmunomodulation.

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

I. Svane, H. Hasselbalch, Ö. Met, 2018, Leukemia.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

P. Ascierto, R. Fisher, A. Ribas, 2019, Nature Medicine.

Functional characterization of Foxp3-specific spontaneous immune responses

I. Svane, A. Woetmann, N. Odum, 2013, Leukemia.

Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy

C. Fegan, M. Donia, I. Svane, 2023, Cell.

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

I. Svane, A. Irmisch, V. Karanikas, 2024, Frontiers in oncology.

Reduced mitochondrial respiration in peripheral T cells after paediatric heamatopoietic stem cell transplantation

I. Svane, Ö. Met, M. Ifversen, 2024, Frontiers in immunology.

Immunotherapy for metastatic colorectal cancer: Present status and new options

I. Svane, P. Straten, M. Andersen, 2012, Scandinavian journal of gastroenterology.

IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition

M. Donia, I. Svane, S. Hadrup, 2024, Frontiers in immunology.

TIL Therapy: Facts and Hopes.

M. Donia, I. Svane, T. Monberg, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

B. Seliger, M. Lauss, M. Donia, 2017, Cancer research.

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

M. Donia, I. Svane, H. Hendel, 2016, Clinical Cancer Research.

Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma.

M. Donia, I. Svane, C. Chamberlain, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials.

M. Donia, H. Schmidt, L. Bastholt, 2017, European journal of cancer.

The Danish Melanoma Database

I. Svane, L. Hölmich, E. Ibfelt, 2016, Clinical epidemiology.

The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors— lessons from normal and immunodeficient mice

I. Svane, A. Engel, I. Svane, 1999, Medical oncology.

Fully automated workflow for integrated sample digestion and Evotip loading enabling high-throughput clinical proteomics

Dorte B. Bekker-Jensen, N. Bache, I. Svane, 2023, bioRxiv.